Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Carlos Barrios
Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
Prof. Carlos Barrios is the director of clinical research and oncologist at the Latin American Cooperative Oncology Group (LACOG) and the director and principal investigator of the Oncology Research Center at Hospital São Lucas, Pontifica Universidade Catolica do Rio Grande do Sul (PUCRS) in Porto Alegre, Brazil. read more
Prof. Barrios’s clinical work is concentrated in the area of breast cancer. He has participated in many clinical research projects and has contributed to numerous abstract presentations and scientific peer reviewed publications. He also has a strong interest in the development of international research collaboration and the implementation of cooperative research infrastructures in Latin America. As such, he is cofounder and current president of LACOG, which unites more than 200 investigators from over 70 institutions across Latin America.
Prof. Barrios is a member of several professional and research organizations. He is an executive board member of the Breast International Group; president elect of the International Education Committee, American Society for Clinical Oncology (ASCO); president of the LACOG; a member of the ASCO Resource Stratified Guideline Advisory Committee and the European Society of Medical Oncology Compliance Committee. He is also on the editorial board of Therapeutic Advances in Medical Oncology and Breast Cancer Research and Treatment.
Prof. Carlos Barrios discloses: Advisory board and consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eisai, GSK, Lilly, MSD, Novartis, Pfizer, Roche/Genentech, Sanofi and Zodiac. Grants/research support (to the institution) from Amgen, AstraZeneca, Aveo Oncology, BioNTech, BMS, Daiichi Sankyo, Dizal Pharma, Exelixis, Fortrea, Gilead Sciences, GSK, ICON, IQVIA, Janssen, Labcorp, Lilly, Medpace, MSD, Novartis, Novocure, Nuvisan, OBI Pharma, Parexel, Pfizer, PharmaMar, PPD, PSI, Regeneron, Roche, Samsung, Sandoz, Sanofi, Seagen, Servier, Stemline, Syneos Health, Takeda, Taiho, Tolmar, TRIO and Worldwide. Ownership or stocks from MEDSir and Tummi.
Prof. Dr. med. Peter Fasching
University Hospital Erlangen and Comprehensive Cancer Center, Erlangen-EMN, Germany
Prof. Dr. med. Fasching is currently the head of the Clinical Trials Unit at Women’s Clinic of the University Hospital Erlangen, is the coordinator to the Breast Cancer Center and Gynaecological Oncology Center, and head of the biomaterial bank. He is also an associate professor of gynaecology, obstetrics and translational medicine at the Friedrich-Alexander University Erlangen-Nuremberg and the National Center for Tumour Diseases WERA in Erlangen, Germany. read more
Prof. Dr. med. Fasching’s research focuses on cancer prevention, target discovery, big data and digital medicine. In 2020, he joined the board of directors of the clinical research organization, Translational Research in Oncology, formerly known as the Breast Cancer International Research Group. He is a member of most national and international societies including American Society for Clinical Oncology, the American Association for Cancer Research, the European Society for Medical Oncology and German Society of Breast Diseases.
Over the past 5 years, he has published more than 840 peer reviewed papers in journals such as the Annals of Oncology, the New England Journal of Medicine, Nature, Nature Genetics, Lancet Oncology, the Journal of Clinical Oncology and the Journal of the National Cancer Institute. He is rated a “Highly Cited Researcher” by Clarivate and was elected to the German National Academy of Sciences, Leopoldina in 2022.
Prof. Dr. med. Peter Fasching discloses: Advisory board or consultancy fees from Agendia, AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Menarini, MSD, Mylan, Novartis, Pfizer, Roche, SeaGen and Veracyte. Speaker’s bureau fees from AstraZeneca, Daiichi Sankyo, Eisai, Gilead, GuardantHealth, Lilly, MSD, Mylan, Novartis, Pfizer, Roche, SeaGen and Veracyte. Grants/research support (to the institution) from BioNtech, Cepheid and Pfizer.
Dr Sonia Pernas
Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
Dr Sonia Pernas is head of the Breast Cancer Unit at the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), in Barcelona, Spain, and is an assistant professor at the University of Barcelona. read more
Dr Pernas has extensive experience in clinical and translational research, having been involved in over 150 phase I–IV breast cancer clinical and window-of-opportunity trials as principal investigator or co-principal investigator. She currently pursues several novel lines of research in breast cancer. She has published widely on HER+ and HER2– breast cancer. Other areas of interest include gene expression; identification of biomarkers of response/resistance to therapy; and molecular characterization of special types of breast cancer, such as metaplastic, secretory or inflammatory breast cancer. She has also collaborated on multiple research projects with national and international research groups.
Dr Pernas has contributed to more than 85 publications in international peer-reviewed journals. She serves as a member of the Executive Board and Scientific Committee for the SOLTI Innovative Breast Cancer Research Group and a member of the American Society for Clinical Oncology,the European Society for Medical Oncology, the Spanish Society for Medical Oncology and the Spanish Breast Cancer Group, GEICAM.
Dr Sonia Pernas discloses: Advisory board or consultancy fees from AstraZeneca, Daiichi Sankyo, Lilly, Pfizer and SeaGen. Speaker’s bureau fees from AstraZeneca–Daiichi Sankyo, Gilead, Lilly, Novartis, Pfizer and Roche. Travel grants from AstraZeneca, Gilead, Novartis, Pfizer and Roche.
